Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Clinical trial NCT06050252 · RECRUITING
Trial details
- NCT number
- NCT06050252
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-10
- Primary completion
- 2027-02-12
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.